Digital breast tomosynthesis plus synthesised two-dimensional mammography
1 paper1 finding
- 1 lab
- Human trial1
Associations
1Invasive interval breast cancers
downin humans1OR 0.76
1 study
Invasive interval breast cancers
downin humans1OR 0.76
Digital breast tomosynthesis plus synthesised two-dimensional mammography lowers the risk of invasive interval breast cancers in humans (Adjusted OR 0.76, 95% CI 0.55–1.06; 14.2 versus 18.6 cases per 10 000 screen-negative women).
Human trialNegative screening result; compared with digital mammographybreast24 monthsfemales
The Lancet. Oncology9 Oct 2026
Latest
1 in 12 monthsThe Lancet Oncology
Invasive interval breast cancer rates after digital breast tomosynthesis plus synthesised mammography versus digital mammography screening (TOSYMA): 24-month follow-up of the multicentre, open-label, randomised, controlled, superiority trial
Randomised trial in 99,558 peopleInterventions